NCT04848935

CURATE.AI COR-Tx Trial for Post Brain Radiotherapy Patients

Status unknown NA Last updated 12 November 2021

What this trial tests

NA trial testing CURATE.AI in Cognitive Decline in 15 participants. Status unknown.

Timeline

14 June 2021

Primary endpoint
1 January 2022

1 July 2022

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	14 June 2021
Primary completion	1 January 2022
Estimated completion	1 July 2022
Sites	2 locations across Singapore

Drugs / interventions tested

• CURATE.AI

Conditions studied

• Cognitive Decline — all drugs for Cognitive Decline →

Sponsor

National University Hospital, Singapore

Who can join

Adults 21 to 99, any sex, with Cognitive Decline. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cognitive deficit is common in patients who have undergone whole brain or partial brain radiotherapy. To counteract intellectual deterioration, the conventional strategies includes drug- based treatments such as donezepil and memantine, which have shown to only provide marginal improvement and, cognitive training regimens, both of which are usually administered at fixed dose/intensities often leading to sub-optimal responses. This study aims to address this clinically relevant problem by harnessing the CURATE.AI platform to identify N-of-1cognitive training profiles the can enhance learning trajectories through individualised calibration and training regimens. CURATE.AI is a phenotypic personalised medicine (PPM) platform that correlates a patient's phenotypic response (cognitive performance) to a certain input (training intensity) based exclusively on the patient's data. This PPM platform is independent of biological system or interventional agent and can be applied to any disorder treatment where dosing/intensity could be better personalised. CURATE.AI is expected to optimise/personalise cognitive training in post-brain radiotherapy patients by dynamically modulating the intensity of a digital cognitive test battery that measures executive processing, multitasking and perceptual learning tasks. In addition, this clinical feasibility trial aims to assess this cognitive test battery as a potential analogous or complementary diagnostic tool as compared to traditional cognitive evaluations performed by a clinician.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial.
   Blasiak A, Tan LWJ, Chong LM, Tadeo X, et al · · 2024 · cited 8× · PMID 39191913 · DOI 10.1038/s41746-024-01195-5
2. Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial.
   Blasiak A, Truong ATL, Foo N, Tan LWJ, et al · · 2025 · cited 6× · PMID 39984618 · DOI 10.1038/s41698-025-00835-7
3. CURATE.AI COR-Tx platform as a digital therapy and digital diagnostic for cognitive function in patients with brain tumour postradiotherapy treatment: protocol for a prospective mixed-methods feasibility clinical trial.
   Remus A, Tadeo X, Kai GNS, Blasiak A, et al · · 2023 · cited 6× · PMID 37879700 · DOI 10.1136/bmjopen-2023-077219
4. N-of-1 medicine.
   Wang P, Leong QY, Lau NY, Ng WY, et al · · 2024 · cited 5× · PMID 38527301 · DOI 10.4103/singaporemedj.smj-2023-243
5. Unique Digital Images as Incentives in Clinical Trials: A Digital Shift Toward Meaningful Participation
   Tadeo X, Seres G, Wang P, Sapanel Y, et al · · 2026
6. CURATE.AI COR-Tx platform as a digital therapy and digital diagnostic for cognitive function in brain tumour patients post-radiotherapy treatment: Protocol for a prospective mixed-methods feasibility clinical trial
   Remus A, Tadeo X, Ng GSK, Blasiak A, et al · · 2023 · DOI 10.21203/rs.3.rs-2322997/v1